Xeris Biopharma Holdings: Pay

Xeris Biopharma Holdings paid its 5 named executives $13.1M in total in FY2025 (Dec). CEO John Shannon was paid $5.0M of that.

Pay$100 in the stock at the end of FY20 → $63
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

John ShannonChief Executive Officer
FY2025 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
3 years
Kevin McCullochPresident and Chief Operating Officer
FY2025 (Dec)
1 year
Anh NguyenChief Medical Officer
FY2025 (Dec)
1 year
Beth P. HechtChief Legal Officer and Corporate Secretary
FY2025 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
3 years
Steven M. PieperChief Financial Officer
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 4 peers with pay on file was $9.3M. CEO pay of Xeris Biopharma Holdings for that year is not on file.

  1. 1Mirum Pharmaceuticals
  2. 2Adma Biologics
  3. 3Travere Therapeutics
  4. 4UroGen Pharma
  5. 5Xeris Biopharma HoldingsNot disclosed
  6. 6Ani PharmaceuticalsNot disclosed
  7. 7Aquestive TherapeuticsNot disclosed
  8. 8AssertioNot disclosed
  9. 9Coherus BioSciencesNot disclosed
  10. 10Collegium PharmaceuticalsNot disclosed
  11. 11HarrowNot disclosed
  12. 12Ironwood PharmaceuticalsNot disclosed
  13. 13Karyopharm TherapeuticsNot disclosed
  14. 14MacroGenicsNot disclosed
  15. 15Ocular PharmaceuticalsNot disclosed
  16. 16Rhythm PharmaceuticalsNot disclosed
  17. 17Y-mAbs TherapeuticsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.